Barclays
MLTX icon

Barclays’s MoonLake Immunotherapeutics MLTX Stock Holding History

Barclays’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Sell
11,908
-15,694
-57% -$284K ﹤0.01% 3617
2026
Q1 		$515K Sell
27,602
-22,649
-45% -$375K ﹤0.01% 3172
2025
Q4 		$662K Buy
50,251
+50,235
+313,969% +$593K ﹤0.01% 3694
2025
Q3 		$115 Sell
16
-4,537
-100% -$236K ﹤0.01% 5267
2025
Q2 		$215K Sell
4,553
-15,046
-77% -$613K ﹤0.01% 4226
2025
Q1 		$766K Buy
19,599
+14,953
+322% +$644K ﹤0.01% 3268
2024
Q4 		$252K Sell
4,646
-995
-18% -$50.8K ﹤0.01% 4201
2024
Q3 		$284K Buy
5,641
+5,229
+1,269% +$245K ﹤0.01% 4117
2024
Q2 		$18.1K Sell
412
-3,367
-89% -$143K ﹤0.01% 4450
2024
Q1 		$190K Sell
3,779
-2,335
-38% -$127K ﹤0.01% 4142
2023
Q4 		$369K Buy
6,114
+2,802
+85% +$144K ﹤0.01% 4064
2023
Q3 		$189K Buy
+3,312
New +$183K ﹤0.01% 3327
2023
Q1 		– Sell
-55,952
Closed -$587K – 5249
2022
Q4 		$587K Buy
55,952
+40,768
+268% +$363K ﹤0.01% 3206
2022
Q3 		$118K Buy
15,184
+101
+0.7% +$714 ﹤0.01% 3472
2022
Q2 		$79K Buy
+15,083
New +$94.8K ﹤0.01% 3865

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's MLTX Position: Q2 2026 in Review

Barclays reduced its MoonLake Immunotherapeutics (MLTX) stake by 57% in Q2 2026, selling an estimated $284K and leaving 11,908 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #3617.

Barclays first reported a position in MLTX in Q2 2022 and has held it in 15 quarters since. The position peaked at $766K in Q1 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Barclays held 11,908 shares of MoonLake Immunotherapeutics worth $232K as of Q2 2026.
  • Barclays sold 15,694 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $284K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3617 holding.
  • Barclays first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 15 quarters since.
  • Barclays's MoonLake Immunotherapeutics position peaked at $766K in Q1 2025.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.